American Cannabis Sales Sink in November

New Cannabis Ventures offers readers this easy-to-read exclusive summary of BDSA’s monthly cannabis sales data for 11 states.

Cannabis sales decreased 2.8% in November compared to October according to cannabis data analytics firm BDSA. Looking at a per-day basis, sales increased 0.5% month-over-month. In this review, we will look at the markets one-by-one, beginning with the eastern markets and then concluding with the western markets. In total, BDSA estimates that sales across the 11 markets totaled $1.60 billion during the month.

Eastern Markets

BDSA provides coverage for Florida, Illinois, Maryland, Massachusetts, Michigan and Pennsylvania. In November, year-over-year growth ranged from -13.1% in Maryland to 37.4% in Florida. Note that Florida, Maryland and Pennsylvania are medical-only markets, though Maryland is introducing adult-use soon.


While sales dipped 2.7% from October, they soared 37.4% from a year ago to $196.1 million. Flower sales grew 44% from a year ago, while pre-rolls grew only 6%. Concentrates expanded by 40%, and ingestibles grew by 32%.


We previously published data released by the state showing that sales fell 0.8% from October and increased 4.2% from November 2021. BDSA estimated sales of$158.7 million, in line with the state-released data. Flower sales expanded by 3% from a year ago, while pre-rolls grew 18%. Concentrate sales gained 7%, while ingestibles fell 2%.


The slumping Maryland medical market fell again, dropping 0.8% sequentially and 13.1% from a year ago to $38.1 million. Flower sales fell 13% from a year ago, and pre-rolls dropped 9%. Concentrate sales fell 18%, while ingestibles fell just 1%.


Sales of $142.8 million fell 3.5% sequentially and rose 1.4% from a year ago. Flower sales grew 6% from November 2021, while pre-rolls expanded by 1%. Concentrates sales were 3% lower, and ingestibles fell 2%.


We had previously written about data released by the state indicating that Michigan cannabis sales fell 2.9% sequentially and  grew 33.2% year-over-year. BDSA estimated sales similar to the state at $203.4 million. Flower sales grew 40% from a year ago, while pre-rolls soared 66%. Concentrates expanded by 23%, and ingestibles grew 9%.


Sales picked up in November, gaining 1.2% sequentially and falling just 6.9% from a year ago to $93.2 million. Flower sales fell 2% from a year ago, ingestibles gained 1% and concentrates declined 12%.

Western Markets

BDSA provides coverage for Arizona, California, Colorado, Nevada and Oregon. In November, year-over-year growth ranged from -23.8% in Nevada to -2.5% in Arizona compared to a year ago.


Combined sales of $106.7 million decreased 1.1% from October and fell 2.5% from a year ago. Medical sales of $37.8 million fell 5% sequentially and 28% from a year ago. Adult-use sales of $68.9 million increased 1% from October and 21% from a year ago. Flower sales fell 11% from a year ago, while pre-rolls soared 31%. Ingestibles gained 7%, and concentrates fell 4%.


Sales fell 3% sequentially to $387 million, down 17.4% from a year ago. Prior data was revised by the state. Flower sales fell 24%, while pre-rolls dropped 9% from a year ago. Concentrates dropped 17%, and ingestibles fell 11%.


Sales of $134.5 million were down 5.3% sequentially and 15.2% from a year ago. Flower sales fell 12% from a year ago, while pre-rolls dropped 16%. Concentrates declined by 15%, and ingestibles plunged 20%.


Nevada sales dropped 4.8% sequentially and 23.8% from a year ago to $62.4 million. Flower sales dropped 28% from a year ago, while pre-rolls fell 19%. Concentrates declined 18%, and ingestibles plunged 26%.


Dropping 5% sequentially, sales of $75.4 million fell 12.7% from a year ago. Flower sales fell 22% from a year ago, while pre-rolls advanced by 7%. Concentrate sales were 13% lower, and ingestibles were unchanged.

For readers interested in a deeper look at cannabis markets across these eleven states and more, including segmentation by additional product categories, brand and item detail, longer history, and segmentation by product attributes, learn how BDSA Solutions can provide you with access to actionable data and analysis.

Exclusive article by Alan Brochstein, CFA
Alan Brochstein, CFA
Based in Houston, Alan leverages his experience as founder of online community 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email

Get Our Sunday Newsletter